Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Levodopa 250 mg and Carbidopa 25 mg
NCT05250141Phase 1Completed
- Sponsor
- Laboratorios Andromaco S.A.
- Start
- Feb 2022
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in Parkinson's disease (PD) comparing Levodopa/Carbidopa Test with Sinemet Reference (2 arms). Primary endpoints: Area under the plasma concentration-time curve from time zero to time t, Area under the plasma concentration-time curve from time zero to infinite and 2 more. Started Feb 2022; status: completed.
02
Drugs
levodopacarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05250141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05250141.